Oncotelic Therapeutics' Nanomedicine Platform Demonstrates Significant Reduction in Gastrointestinal Drug Accumulation

Oncotelic Therapeutics Inc. has unveiled new data demonstrating the capabilities of its Deciparticle nanomedicine platform, which reliably formulates diverse hydrophobic drugs into uniform, intravenous-ready nanoparticles. The platform's most notable achievement involves Sapu003, the intravenous Deciparticle formulation of Everolimus, which preclinical pharmacokinetic data show reduces gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. This advancement represents a significant step forward in drug delivery technology with implications for patient safety and treatment efficacy.

The company presented this data at the 2025 San Antonio Breast Cancer Symposium, highlighting how the Deciparticle platform can package water-resistant drugs into smaller, uniform nanoparticles suitable for intravenous administration. According to information available at https://ibn.fm/LxQ7N, this technology addresses a fundamental challenge in pharmaceutical development: delivering hydrophobic compounds effectively through intravenous routes rather than relying on oral administration with its associated gastrointestinal side effects.

The platform demonstrates remarkable compatibility across multiple therapeutic categories, successfully formulating all five main macrolide mTOR inhibitors into stable, monodisperse particles. These include temsirolimus, sirolimus, ridaforolimus, Everolimus, and umirolimus. Additionally, the platform effectively formulates tacrolimus, another key therapeutic agent. This broad compatibility suggests the technology could revolutionize how numerous existing drugs are administered, potentially improving their safety profiles and therapeutic outcomes.

The implications of this development extend beyond technical achievement to practical patient benefits. By reducing gastrointestinal drug accumulation by such a significant margin, the technology could minimize side effects commonly associated with oral administration of these potent medications. For oncology and immunology patients already dealing with challenging treatment regimens, this could mean improved quality of life during therapy and potentially better adherence to prescribed treatment protocols.

Oncotelic Therapeutics' expanding pipeline, built on this modular, cGMP-ready nanomedicine engineering platform, positions the company at the forefront of next-generation drug delivery systems. The ability to transform hydrophobic drugs into intravenous formulations opens new possibilities for drug development and administration that could benefit numerous patient populations. As the company continues to develop its technology, the broader pharmaceutical industry may need to reconsider traditional drug delivery approaches in favor of more targeted, efficient methods that minimize systemic side effects while maximizing therapeutic impact.